Trial Profile
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Oct 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Paclitaxel (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Trastuzumab emtansine (Primary)
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms IMpassion050
- Sponsors Chugai Pharmaceutical; Roche
- 14 Sep 2023 Status changed from active, no longer recruiting to completed.
- 24 Aug 2023 The study has been completed in Germany , according to European Clinical Trials Database record.
- 12 May 2023 Planned End Date changed from 24 Aug 2023 to 31 Aug 2023.